Swedish Orphan Biovitrum starts phase 3 study of avatrombopag in children with ITP

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Source:
    Nordic Business Report (M2). 03/12/2021.
  • Additional Information
    • Abstract:
      Biopharmaceutical company Swedish Orphan Biovitrum AB (Sobi) (STO:SOBI) reported on Friday that the first patient has been dosed in a phase 3 study of Doptelet (avatrombopag) in children with immune thrombocytopenia (ITP).